2025 ESMO Congress: Focus on Breast Cancer

Benjamin P. Levy, MD leads a live CFS discussion with Kamel Abou Hussein, MD and Victoria Rizk, MD on the evolving therapeutic landscape in breast cancer.

Use of camizestrant plus a CDK4/6 inhibitor at the emergence of an ESR1 mutation did not significantly worsen visual symptoms in HR-positive breast cancer.

Erica L. Mayer, MD, MPH, discussed PRO data in ESR1 mutation–emergent breast cancer following switch therapy to camizestrant plus a CDK4/6 inhibitor.

Paolo Tarantino, MD, PhD, discussed the clinical implications of the DESTINY-Breast11 trial of T-DXd/THP in high-risk, HER2-positive early breast cancer.

Sara M. Tolaney, MD, MPH, discussed the use of T-DXd in patients with HER2-positive breast cancer with residual disease after neoadjuvant therapy.

Rebecca Dent, MD, MSc, FRCP, discussed the future implications of data with first-line Dato-DXd in locally recurrent inoperable or metastatic TNBC.

Kelly E. McCann, MD, PhD, discusses findings from the VIKTORIA-1 trial of gedatolisib-based regimens in hormone receptor–positive advanced breast cancer.

Vepdegestrant maintained QOL and reduced risk of symptom deterioration vs fulvestrant in ESR1-mutated ER-positive, HER2-negative advanced breast cancer.

Switching to camizestrant plus a CDK4/6 inhibitor delayed symptom deterioration and improved QOL in HR+ breast cancer with the emergence of ESR1 mutations.

Gedatolisib plus fulvestrant, with or without palbociclib, improved PFS in pretreated, HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.

Sac-TMT bested chemotherapy in terms of PFS in previously treated HR+, HER2– metastatic breast cancer.

Neoadjuvant T-DXd followed by THP improved pathological complete response rate in high-risk, HER2-positive early-stage breast cancer.

T-DXd significantly improved IDFS vs T-DM1 in high-risk, HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy.

Giredestrant plus everolimus improved progression-free survival in ER-positive, HER2-negative advanced breast cancer after a prior CDK4/6 inhibitor.

Joyce A. O’Shaughnessy, MD, highlights the breast cancer data being presented at ESMO 2025 that have the greatest potential to shape clinical practice.